BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

Head and neck cancer clinical trials and catalysts

Active industry-sponsored trials on ClinicalTrials.gov for head and neck cancer: 424 (262 sponsors; 54 newly posted in the last 180 days, 20 stopped in the last 180 days; 27 new-entrant sponsors). Momentum score 9.3, rank 75 of 91 on the disease-area ranking. As of 2026-11-18.

Phase distribution: Early Phase 1 6, Phase 1 144, Phase 2 173, Phase 3 47, Phase 4 5, N/A 49.

Most active sponsors, by phase

SponsorActive trialsBy phaseNew (window)Upcoming readouts
Sichuan Baili Pharmaceutical Co., Ltd.24P2 12, P1 8, P3 457
CSPC Megalith Biopharmaceutical Co.,Ltd.6P3 4, P2 230
AstraZeneca AZN11P2 3, P3 3, NA 1, P1 402
Exelixis EXEL6P3 2, P1 3, P4 102
Genmab GMAB4P3 2, P2 200
Lepu Biopharma Co., Ltd.4P2 2, P3 200
Akeso3P2 1, P3 202
Rakuten Medical, Inc.3P3 2, P2 100
Merck Sharp & Dohme LLC MRK7P2 6, P3 101
Bicara Therapeutics BCAX3P2 1, P3 1, P1 110
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.3P2 1, NA 1, P3 102
Daiichi Sankyo3P3 1, P2 200
GlaxoSmithKline3P3 1, P1 1, P2 100
Hansoh BioMedical R&D Company3P2 2, P3 110
Jazz Pharmaceuticals JAZZ3P3 1, NA 1, P2 111
MediLink Therapeutics (Suzhou) Co., Ltd.3P2 2, P3 100
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. SKBBY3P2 2, P3 120
Aveta Biomics, Inc.2P2 1, P3 111
Beijing Konruns Pharmaceutical Co., Ltd.2P3 1, P2 101
Inhibrx Biosciences, Inc INBX2P2 1, P3 100
Janssen Research & Development, LLC2P2 1, P3 100
Johnson & Johnson Enterprise Innovation Inc. JNJ2P3 1, P1 100
Qilu Pharmaceutical Co., Ltd.2P3 1, P1 100
AVEO Pharmaceuticals, Inc.1P3 100
BioNTech SE BNTX1P3 100

Recently stopped trials

Upcoming trial readouts (next 90 days)

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-11-22 est.P2Shanghai Henlius BiotechNCT06839066 A Phase II Study to Evaluate HLX43 in Subjects With Recurrent/Metastatic Nasopharyngeal Carcinoma Failed or Intolerance to Second-line TherapyNasopharyngeal Carcinoma (NPC)recruiting70
2026-12 est.P2Sichuan Baili Pharmaceutical Co., Ltd.NCT05054439 A Clinical Study of SI-B001 in Combination With Paclitaxel/Docetaxel in the Treatment of Recurrent and Metastatic HNSCCHead and Neck Squamous Cell Carcinomaactive not recruiting45
2026-12 est.P2Aveta Biomics, Inc.NCT05312710 Safety and Efficacy of APG-157 in Head and Neck CancerHead and Neck Cancer; Squamous Cell Carcinoma of Oral Cavity; Squamous Cell Carcinoma of the Oropharactive not recruiting24
2026-12 est.P1/P2AP Biosciences Inc.NCT05473156 A Study to Investigate the Safety, Pharmacokinetics, and Clinical Activity of AP203 in Patients with Locally Advanced or Metastatic Solid Tumors, and Expansion Locally Advanced or Metastatic Solid Tumors; Non Small Cell Lung Cancer (NSCLC); Head and Neck Squamrecruiting168
2026-12 est.P1/P2Sichuan Baili Pharmaceutical Co., Ltd.NCT05668858 A Study of SI-B001+SI-B003± Chemotherapy in Patients With Locally Advanced or Metastatic Head and Neck Squamous Cell CarcinomaSquamous Cell Carcinoma of Head and Neckactive not recruiting70
2026-12 est.P1/P2TiumBio Co., Ltd.NCT05784688 Study of TU2218 in Combination With KEYTRUDA®(Pembrolizumab) in Patients With Advanced Solid TumorsSolid Tumor; Biliary Tract Cancer; Head and Neck Squamous Cell Carcinoma; Colorectal Cancerrecruiting140
2026-12 est.P2Sichuan Baili Pharmaceutical Co., Ltd.NCT05956587 A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid TumNon-small Cell Lung Cancer; Nasopharyngeal Carcinomarecruiting121
2026-12 est.P2Sichuan Baili Pharmaceutical Co., Ltd.NCT06006169 A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid TumorsHead and Neck Squamous Cell Carcinomarecruiting186
2026-12 est.P1/P2Theravectys S.A.NCT06319963 A Study to Evaluate Lenti-HPV-07 Immunotherapy Against HPV+ Cervical or Oropharyngeal CancerHPV-Related Cervical Carcinoma; HPV Positive Oropharyngeal Squamous Cell Carcinomarecruiting72
2026-12 est.P1/P2SCG Cell Therapy Pte. Ltd.NCT06505551 Phase 1/2 Study of Autologous SCG142 TCR T Cells in Patients With HPV16/52-positive CarcinomaHPV-Related Squamous Cell Carcinoma; HPV-Related Cervical Squamous Cell Carcinoma; HPV-Related Vulvanot yet recruiting66
2026-12 est.P1/P2AkesoNCT06943820 AK129 Combination Therapy for Advanced Solid TumorsNon-small Cell Lung Cancer Stage IIIB/IV; Head and Neck Squamous Cell Carcinoma (HNSCC); Colorectal recruiting230
2026-12 est.P1/P2One-carbon Therapeutics ABNCT07151040 Phase 1/2 Study to Evaluate TH9619 in the Treatment of Advanced Solid TumorsSolid Tumor; Colorectal Cancer (CRC); Squamous Cell Carcinoma of Head and Neck; Non-Small Cell Lung recruiting43
2026-12-15 est.P1/P2PMV Pharmaceuticals, Inc PMVPNCT04585750 The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)Advanced Solid Tumor; Advanced Malignant Neoplasm; Metastatic Cancer; Metastatic Solid Tumor; Lung Crecruiting300
2026-12-15 est.P1/P2GV20 TherapeuticsNCT05669430 A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor MalignanciesSolid Tumor, Adult; Refractory Cancer; Endometrial Carcinoma (EC); Squamous Head and Neck Carcinoma;recruiting365
2026-12-30 est.P2NATCO Pharma Ltd.NCT05283226 Study to Evaluate the Safety and Efficacy of Oral NRC-2694-A in Combination With Paclitaxel in Patients With Recurrent and/or Metastatic Head and Neck Squamous Carcinoma; Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinomarecruiting21
2026-12-31 est.P1/P2OncoC4, Inc.NCT04140526 Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLCNon Small Cell Lung Cancer; Advanced Solid Tumor; Metastatic Melanoma; Metastatic Head and Neck Carcactive not recruiting733
2026-12-31 est.P1/P2BicycleTx LimitedNCT04180371 Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 ExpressionAdvanced Solid Tumor Historically Known for High EphA2 Expression; Urothelial Cancer; Ovarian Canceractive not recruiting288
2026-12-31 est.P2Valenta Pharm JSCNCT06843018 Study to Evaluate the Efficacy and Safety of Different Doses of Graminidin With Anesthetic, a Metered Dose Topical Spray, in the Treatment of Acute Infectious aPharyngitis Acute; Pharyngitis; Nasopharyngitis; Exacerbation of Chronic Pharyngitisrecruiting300
2027-01 est.P3AkesoNCT06601335 A Phase 3 Study of AK112 Plus AK117 Versus Pembrolizumab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)Head and Neck Squamous Cell Carcinomarecruiting510
2027-01-30 est.P1/P2Psivac LtdNCT06549946 Ixovex-1 Single Agent and Combination TherapySolid Tumor; Head and Neck Cancerrecruiting18
2027-02 est.P1/P2GI Innovation, Inc.NCT07172802 A Study of GI-108, an Anti-CD73-IgG4 Fc-IL-2v Bispecific Fusion Protein, as Monotherapy in Patients With Advanced or Metastatic Solid TumorsAdvanced Solid Tumor; Metastatic Solid Tumor; Non-small Cell Lung Cancer (NSCLC); Head and Neck (HNSrecruiting102

Readouts in the last 180 days

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-11 est.P2Sichuan Baili Pharmaceutical Co., Ltd.NCT06668961 A Study of SI-B001+SI-B003 Combined With Platinum-based Chemotherapy as First-line Treatment in Patients With Recurrent or Metastatic Head and Neck Squamous CelHead and Neck Squamous Cell Carcinomaactive not recruiting48
2026-11 est.P3Sichuan Baili Pharmaceutical Co., Ltd.NCT06118333 A Study Comparing BL-B01D1 With Physician's Choice of Chemotherapy in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma(PANKU-NPC01)Nasopharyngeal Carcinomaactive not recruiting386
2026-11 est.P2MediLink Therapeutics (Suzhou) Co., Ltd.NCT06107686 A Study of YL202 in Selected Patients With Advanced Solid TumorsNSCLC; Breast Cancer; HNSCC; Locally Advanced or Metastatic Solid Tumorsrecruiting200
2026-10-29P2Hoffmann-La RocheNCT02568267 Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (FusioBreast Cancer; Cholangiocarcinoma; Colorectal Cancer; Head and Neck Neoplasms; Lymphoma, Large-Cell,completed534
2026-10-01P1/P2Merus B.V.NCT04868877 Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in CombinationNon-Small Cell Lung Cancer Metastatic; Gastric Cancer; Esophageal Squamous Cell Carcinoma; Head and terminated194
2026-10 est.P2Vyriad, Inc.NCT04291105 Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer PatientsMelanoma; Head and Neck Squamous Cell Carcinoma; Colo-rectal Canceractive not recruiting87
2026-09-22 est.P1/P2ImmVira Pharma Co. LtdNCT04370587 A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or MeSolid Tumor; Melanoma; HNSCC; Sarcoma; Squamous Cell Carcinoma; NSCLCrecruiting30
2026-09-10P2GlaxoSmithKlineNCT06062420 A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma ofNeoplasms, Head and Neckactive not recruiting316
2026-09 est.P3CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.NCT05717764 Clinical Study of Mitoxantrone Hydrochloride Liposome Injection Combined With Capecitabine Versus Capecitabine Monotherapy in Patients With Recurrent MetastaticRecurrent Metastatic Nasopharyngeal Carcinomanot yet recruiting500
2026-08-25P3PDS Biotechnology Corp. PDSBNCT06790966 Phase 3 Study of PDS0101 and Pembrolizumab in HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell CarcinomaRecurrent Head and Neck Cancer; Metastatic Head and Neck Cancer; HPV Positive Oropharyngeal Squamousterminated12
2026-07-30 est.P2Shanghai Institute Of Biological ProductsNCT06194656 Clinical Trial of SIBP-03 in Patients With Head and Neck Squamous Cell CarcinomaHead and Neck Squamous Cell Carcinomarecruiting81
2026-07-01 est.P1/P2Scancell Ltd SCNLDNCT05329532 Modi-1 Moditope in Breast, Head and Neck, Ovarian, or Renal CancerTriple Negative Breast Cancer; Renal Cell Cancer; High Grade Ovarian Serous Adenocarcinoma; Squamousrecruiting168
2026-07 est.P1/P2CJ Bioscience, Inc.NCT05877430 Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic CancerNSCLC; HNSCC; Melanoma; Metastatic Cancer; Advanced Solid Tumor; Advanced Cancerrecruiting160
2026-06-17P1/P2Precision Biologics, Inc DTILNCT03476681 Study of NEO-201 in Solid Tumors Expansion CohortsNon Small Cell Lung Cancer; Head and Neck Squamous Cell Carcinoma; Cervical Cancer; Uterine Canceractive not recruiting121
2026-06-02P1/P2Sensei Biotherapeutics, Inc.NCT05864144 A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid TumorsSolid Tumor, Adult; Advanced Solid Tumor; Head and Neck Cancer; Breast Cancer; Colon Cancer; Pancreacompleted98
2026-06 est.P1/P2Volastra Therapeutics, Inc.NCT05902988 A Phase I/II Study of VLS-1488 in Subjects With Advanced CancerAdvanced Solid Tumor; High Grade Serous Adenocarcinoma of Ovary; Squamous Non-small-cell Lung Cancerrecruiting200
2026-06 est.P1/P2Rakuten Medical, Inc.NCT04305795 An Open-label Study Using ASP-1929 Photoimmunotherapy in Combination With Anti-PD1 Therapy in EGFR Expressing Advanced Solid TumorsRecurrent Head and Neck Squamous Cell Carcinoma; Metastatic Head-and-neck Squamous-cell Carcinoma; Lactive not recruiting23
2026-06 est.P2Sound Pharmaceuticals, Incorporated SOGPNCT01451853 SPI-1005 for Prevention and Treatment of Chemotherapy Induced Hearing LossLung Cancer; Head and Neck Cancer; Hearing Loss; Ototoxicity; Tinnitus; Neuropathywithdrawn

Landscape counts: ClinicalTrials.gov, industry lead sponsors, active statuses, via the free hosted BioCatalystFeed MCP tool condition_landscape (query "head and neck cancer"); readouts matched by condition text. Registry counts only; not a forecast.

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.